Pfizer claims promising results for maternal RSV vaccine in protecting infants

Published



Pfizer’s vaccine against respiratory syncytial virus, or RSV, showed promising results protecting newborns when the shot is administered to mothers during the late stages of their pregnancies, according to new clinical trial data from the company.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.